Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 410
interventional 358
Observational 49
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 192
Biological 26
Drug|Procedure 22
Drug|placebo 20
Procedure 12
Biological|Drug|Procedure|Radiation 9
Drug|Other 9
Device 8
Other 8
Biological|Drug|Procedure 7
Biological|placebo 5
Drug|Procedure|Radiation 5
Biological|Drug 3
Biological|Other 3
Biological|Procedure 3
Drug|Radiation 3
Biological|Drug|Other|Procedure|Radiation 2
Biological|Drug|placebo 2
Biological|Drug|Radiation 2
Biological|Other|Procedure 2
Drug|Other|Procedure|Radiation 2
Behavioral|Drug 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other 1
Biological|Genetic|Other|Procedure 1
Biological|placebo|Procedure 1
Dietary Supplement 1
Dietary Supplement|Other 1
Drug|Other|placebo|Procedure 1
Drug|Other|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Genetic 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 231
France 11
China 8
Germany 8
NA 7
Israel 6
Spain 6
Italy 5
Korea, Republic of 5
Belgium 4
Japan 4
United States|Canada 4
Belgium|Netherlands 3
Brazil 3
Russian Federation 3
Austria 2
Canada 2
Mexico 2
Norway 2
United Kingdom 2
United States|Australia|Canada 2
Australia|Belgium|Bulgaria|Chile|China|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Portugal|Russian Federation|South Africa|Spain|Sweden|Thailand|Turkey 1
Australia|Belgium|Canada|Chile|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Slovenia|Spain 1
Australia|United Kingdom 1
Brazil|Czechia|India|Japan|Korea, Republic of|Russian Federation|Slovakia|Spain|Switzerland|Taiwan|Thailand 1
Brazil|Mexico 1
Bulgaria|United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|India|Israel|Italy|Japan|Jordan|Korea, Republic of|Netherlands|Norway|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
France|Belgium 1
Germany|Israel 1
Germany|Netherlands 1
Hong Kong 1
India 1
Israel|Italy 1
Israel|Italy|Australia|Austria|Bulgaria|Canada|Czechia|Denmark|France|Germany|Greece|Hong Kong|Japan|Korea, Republic of|Netherlands|Norway|Portugal|Russian Federation|Saudi Arabia|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
Japan|United States|Belgium|France 1
Malaysia 1
Netherlands 1
Norway|Sweden 1
Pakistan 1
Sweden 1
Taiwan 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Norway|Poland|Portugal|Romania|Russian Federation|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Czechia|Finland|France|Germany|Greece|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|China|Croatia|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Singapore|Spain|Taiwan 1
United States|Australia|Austria|Canada|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Russian Federation|Spain|United Kingdom 1
United States|Australia|Austria|France|Germany|Italy|Portugal|Slovakia|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Greece|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey 1
United States|Australia|Brazil|Germany|Italy|Portugal|Slovakia|Turkey|United Kingdom 1
United States|Australia|Canada|Italy|Switzerland|United Kingdom 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|New Zealand|Saudi Arabia 1
United States|Australia|Spain 1
United States|Austria|Belgium|Bulgaria|Canada|Croatia|France|Germany|Greece|Italy|Poland|Portugal|Spain|United Kingdom 1
United States|Austria|France|Germany|Hungary|Italy|Spain|United Kingdom 1
United States|Belgium|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|France 1
United States|France|Germany|Italy|Spain 1
United States|Italy 1

Sites per Study

Site_count Study_Count
1 204
2 33
3 9
4 12
5 10
6 10
7 8
8 8
9 1
10 4
11 1
12 2
13 4
14 6
15 4
16 3
17 3
18 1
19 1
20 2
21 1
22 1
23 1
24 1
25 2
28 1
30 1
31 4
32 1
36 1
38 1
39 1
44 1
48 2
50 1
53 1
62 1
70 1
76 1
92 1
104 2
111 1
114 1
129 1
164 1
191 1

Phase

Phase Study_Count
Phase 2 149
Phase 1/Phase 2 57
Phase 1 50
Phase 3 45
N/A 32
Phase 4 12
Phase 2/Phase 3 7
Early Phase 1 6

Number of Arms

Number_of_Arms Count_of_Studies
1 150
2 104
3 22
4 4
5 2
6 1
7 1
8 1
25 1
NA 72

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00000 3.00 4.00000 3.00000 3.00000 50.0000 6.0000 3.00
1st Qu. 16.50000 19.25 15.00000 20.00000 25.00000 61.2500 61.0000 43.50
Median 21.50000 29.00 24.00000 39.00000 40.00000 122.5000 162.5000 180.00
Mean 25.66667 60.90 27.91489 46.66667 54.62069 134.3333 196.6429 212.25
3rd Qu. 28.00000 68.25 32.00000 52.75000 70.00000 150.7500 255.5000 370.00
Max. 60.00000 450.00 110.00000 400.00000 279.00000 310.0000 769.0000 500.00

Trial Group Type

group_type Group_Count
Experimental 368
NA 72
Active Comparator 59
Placebo Comparator 31
Other 29
No Intervention 8
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 198
Parallel Assignment 107
NA 35
Sequential Assignment 15
Crossover Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 247
Prevention 61
Supportive Care 33
NA 7
Other 5
Diagnostic 4
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 32
Italy 4
NA 3
France 2
Canada 1
China 1
Israel 1
Korea, Republic of 1
Singapore 1
Spain 1
United States|Austria|Canada 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 35
2 6
3 1
5 1
7 1
9 2
14 1
25 1
53 1

Enrollment Metrics

Measure Observational
Min 3.0000
1st Qu 30.0000
Median 100.0000
Mean 653.7959
3rd Qu 383.0000
Max 9999.0000

Observation Model

observational_model Study_Count
Cohort 25
Case-Only 13
Case-Control 6
NA 3
Case Control 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 42
Cross-Sectional 5
Retrospective 1
NA 1

Registries

Studies by Country

Country Study_Count
China 1
NA 1
Taiwan 1

Sites per Study

Site_count Study_Count
1 3

Enrollment Metrics

Measure Registries
Min 30.00000
1st Qu 40.00000
Median 50.00000
Mean 47.33333
3rd Qu 56.00000
Max 62.00000

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
1 Year 2
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04167514 Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone https://ClinicalTrials.gov/show/NCT04167514 Recruiting CSL Behring 2023-11-30
NCT03774082 Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03774082 Recruiting Novartis 2023-12-22
NCT03755414 Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT03755414 Recruiting Washington University School of Medicine 2022-06-30
NCT03640481 Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy https://ClinicalTrials.gov/show/NCT03640481 Active, not recruiting Kadmon Corporation, LLC 2020-09-30
NCT03395860 Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT https://ClinicalTrials.gov/show/NCT03395860 Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 2020-05-20
NCT03395340 Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT03395340 Recruiting National Institutes of Health Clinical Center (CC) 2020-10-01
NCT03371667 To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids https://ClinicalTrials.gov/show/NCT03371667 Recruiting Assistance Publique - Hôpitaux de Paris 2021-09-30
NCT03367962 Detection of Graft Versus Host Disease With [18F]F-AraG https://ClinicalTrials.gov/show/NCT03367962 Recruiting CellSight Technologies, Inc. 2019-12-31
NCT03357159 Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation https://ClinicalTrials.gov/show/NCT03357159 Recruiting Sheba Medical Center 2020-12-01
NCT03340155 Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases https://ClinicalTrials.gov/show/NCT03340155 Recruiting Medical University of Graz 2022-10-31
NCT03327857 Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT03327857 Recruiting AbGenomics International, Inc. 2020-04-30
NCT03320642 GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease https://ClinicalTrials.gov/show/NCT03320642 Recruiting Incyte Corporation 2020-07-31
NCT03315741 The Safety and Tolerability of Pirfenidone for BOS After HCT https://ClinicalTrials.gov/show/NCT03315741 Recruiting Stanford University 2020-01-31
NCT03298815 Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED) https://ClinicalTrials.gov/show/NCT03298815 Recruiting University of Utah 2024-11-30
NCT03263767 Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC https://ClinicalTrials.gov/show/NCT03263767 Recruiting Nantes University Hospital 2021-04-30
NCT03229200 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. https://ClinicalTrials.gov/show/NCT03229200 Enrolling by invitation Pharmacyclics Switzerland GmbH 2027-07-02
NCT03225417 Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. https://ClinicalTrials.gov/show/NCT03225417 Recruiting Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2022-04-16
NCT03207958 Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT03207958 Recruiting Washington University School of Medicine 2021-07-31
NCT03204721 Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis https://ClinicalTrials.gov/show/NCT03204721 Active, not recruiting Oslo University Hospital 2021-12-31
NCT03158896 Evaluation of Umbilical Cord-Derived Wharton’s Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT03158896 Active, not recruiting University of Kansas Medical Center 2020-08-31
NCT03139604 GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03139604 Active, not recruiting Incyte Corporation 2019-05-02
NCT03128359 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03128359 Recruiting City of Hope Medical Center 2021-01-31
NCT03112603 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) https://ClinicalTrials.gov/show/NCT03112603 Active, not recruiting Incyte Corporation 2020-05-27
NCT03109353 Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT03109353 Active, not recruiting St. Olavs Hospital 2020-09-30
NCT03093805 Topical Vitamin D in Acute Graft Versus Host Disease of the Skin https://ClinicalTrials.gov/show/NCT03093805 Completed Children’s Hospital Medical Center, Cincinnati 2019-03-04
NCT03083574 Extracorporeal Photopheresis Using Theraflex ECPâ„¢ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT03083574 Recruiting Jules Bordet Institute 2022-09-30
NCT03057054 Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03057054 Recruiting Children’s Oncology Group 2023-08-01
NCT03007238 Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03007238 Active, not recruiting City of Hope Medical Center 2020-12-31
NCT02997280 Ruxolitinib for Steroid-refractory GVHD https://ClinicalTrials.gov/show/NCT02997280 Completed St. Petersburg State Pavlov Medical University 2018-12-31
NCT02966301 Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide https://ClinicalTrials.gov/show/NCT02966301 Active, not recruiting Medsenic 2020-06-30
NCT02959944 Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD https://ClinicalTrials.gov/show/NCT02959944 Active, not recruiting Pharmacyclics LLC. 2020-07-31
NCT02945176 Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation https://ClinicalTrials.gov/show/NCT02945176 Completed Implandata Ophthalmic Products GmbH 2017-06-14
NCT02942173 CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT https://ClinicalTrials.gov/show/NCT02942173 Active, not recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology 2019-08-21
NCT02923375 A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02923375 Active, not recruiting Cynata Therapeutics Limited 2018-08-28
NCT02918188 Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD https://ClinicalTrials.gov/show/NCT02918188 Recruiting Navy General Hospital, Beijing 2026-01-31
NCT02891395 Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host https://ClinicalTrials.gov/show/NCT02891395 Completed University Hospital, Lille 2017-07-26
NCT02876679 Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT https://ClinicalTrials.gov/show/NCT02876679 Recruiting Assistance Publique - Hôpitaux de Paris 2020-02-29
NCT02867384 Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02867384 Recruiting Dana-Farber Cancer Institute 2022-02-28
NCT02849886 T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. https://ClinicalTrials.gov/show/NCT02849886 Recruiting Centre Hospitalier Universitaire de Besancon 2020-12-31
NCT02828878 Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02828878 Recruiting Cellect Biotechnology 2020-07-31
NCT02824653 Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD https://ClinicalTrials.gov/show/NCT02824653 Completed National Institute of Blood and Marrow Transplant (NIBMT), Pakistan 2016-07-31
NCT02805946 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections https://ClinicalTrials.gov/show/NCT02805946 Completed Radboud University 2019-07-26
NCT02759731 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02759731 Recruiting National Institutes of Health Clinical Center (CC) 2022-06-01
NCT02749084 Multiple Donor Treg DLI for Severe Refractory Chronic GVHD https://ClinicalTrials.gov/show/NCT02749084 Recruiting Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 2020-03-31
NCT02743351 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02743351 Recruiting Fate Therapeutics 2020-04-30
NCT02737306 Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton https://ClinicalTrials.gov/show/NCT02737306 Recruiting CytoDyn, Inc. 2019-12-31
NCT02707354 Early Detection of Mucosal Abnormalities in Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT02707354 Completed Nantes University Hospital 2018-08-20
NCT02687646 Clinical Trial With MSC for Graft Versus Host Disease Treatment https://ClinicalTrials.gov/show/NCT02687646 Recruiting Andalusian Network for Design and Translation of Advanced Therapies 2022-06-30
NCT02683525 Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02683525 Active, not recruiting Indiana University 2019-02-13
NCT02669251 Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02669251 Recruiting National Institutes of Health Clinical Center (CC) 2020-09-30
NCT02663622 Phase II Trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT https://ClinicalTrials.gov/show/NCT02663622 Active, not recruiting OncoImmune, Inc. 2020-11-30
NCT02660684 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor https://ClinicalTrials.gov/show/NCT02660684 Completed Astellas Pharma Inc 2010-02-28
NCT02659657 Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation https://ClinicalTrials.gov/show/NCT02659657 Recruiting Peking University People’s Hospital 2020-06-30
NCT02652130 Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD https://ClinicalTrials.gov/show/NCT02652130 Completed Mesoblast, Ltd. 2018-06-15
NCT02641236 Gut Decontamination In Pediatric Allogeneic Hematopoietic https://ClinicalTrials.gov/show/NCT02641236 Recruiting Dana-Farber Cancer Institute 2021-04-30
NCT02614612 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD https://ClinicalTrials.gov/show/NCT02614612 Completed Incyte Corporation 2016-06-30
NCT02913261 Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02913261 Active, not recruiting Novartis 2019-06-24
NCT02891603 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression https://ClinicalTrials.gov/show/NCT02891603 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-31
NCT02867800 Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease https://ClinicalTrials.gov/show/NCT02867800 Active, not recruiting Columbia University 2021-06-30
NCT02588339 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention https://ClinicalTrials.gov/show/NCT02588339 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2018-12-07
NCT02340676 A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD https://ClinicalTrials.gov/show/NCT02340676 Active, not recruiting Dana-Farber Cancer Institute 2017-08-31
NCT01937468 Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease https://ClinicalTrials.gov/show/NCT01937468 Active, not recruiting Dana-Farber Cancer Institute 2017-08-31
NCT01366092 Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease https://ClinicalTrials.gov/show/NCT01366092 Active, not recruiting Dana-Farber Cancer Institute 2014-10-31
NCT02513498 Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT02513498 Completed Fred Hutchinson Cancer Research Center 2018-01-05
NCT02511782 Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD https://ClinicalTrials.gov/show/NCT02511782 Completed Children’s Hospital Medical Center, Cincinnati 2014-06-30
NCT02491359 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT02491359 Completed Fred Hutchinson Cancer Research Center 2018-02-19
NCT02483702 Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair https://ClinicalTrials.gov/show/NCT02483702 Completed Valley Anesthesiology Consultants 2017-05-11
NCT02423915 Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention https://ClinicalTrials.gov/show/NCT02423915 Active, not recruiting M.D. Anderson Cancer Center 2020-12-30
NCT02027805 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD https://ClinicalTrials.gov/show/NCT02027805 Completed Xenikos 2016-09-07
NCT02406651 Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD https://ClinicalTrials.gov/show/NCT02406651 Active, not recruiting Generon (Shanghai) Corporation Ltd. 2019-04-09
NCT02386800 CINC424A2X01B Rollover Protocol https://ClinicalTrials.gov/show/NCT02386800 Recruiting Novartis 2025-09-17
NCT02359929 BMT Autologous MSCs for GvHD https://ClinicalTrials.gov/show/NCT02359929 Recruiting Emory University 2020-11-30
NCT02345850 Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301) https://ClinicalTrials.gov/show/NCT02345850 Active, not recruiting National Heart, Lung, and Blood Institute (NHLBI) 2020-09-30
NCT02342613 Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT02342613 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2023-01-31
NCT02337595 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02337595 Completed Federal Research Institute of Pediatric Hematology, Oncology and Immunology 2015-03-31
NCT02250300 MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation https://ClinicalTrials.gov/show/NCT02250300 Active, not recruiting Medical College of Wisconsin 2021-09-30
NCT02248597 Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases https://ClinicalTrials.gov/show/NCT02248597 Recruiting Wake Forest University Health Sciences 2020-09-30
NCT02208037 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) https://ClinicalTrials.gov/show/NCT02208037 Completed National Heart, Lung, and Blood Institute (NHLBI) 2017-10-31
NCT02206035 Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02206035 Completed Medical College of Wisconsin 2018-09-30
NCT02195869 Study of the Bruton’s Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02195869 Completed Pharmacyclics LLC. 2017-09-15
NCT02193880 Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) https://ClinicalTrials.gov/show/NCT02193880 Completed University of Alabama at Birmingham 2018-03-13
NCT02176031 Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD https://ClinicalTrials.gov/show/NCT02176031 Completed Dana-Farber Cancer Institute 2019-02-28
NCT02172768 Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease https://ClinicalTrials.gov/show/NCT02172768 Completed Radboud University 2016-06-30
NCT02145403 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02145403 Active, not recruiting University of Michigan Rogel Cancer Center 2018-11-26
NCT02144701 Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02144701 Completed Rutgers, The State University of New Jersey 2016-02-28
NCT02144025 Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT https://ClinicalTrials.gov/show/NCT02144025 Completed Hospital Universitario Dr. Jose E. Gonzalez 2016-02-29
NCT02133924 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT02133924 Recruiting Icahn School of Medicine at Mount Sinai 2020-12-31
NCT02117115 Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02117115 Completed Washington University School of Medicine 2014-10-31
NCT02105766 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure https://ClinicalTrials.gov/show/NCT02105766 Recruiting National Institutes of Health Clinical Center (CC) 2021-08-31
NCT01318330 Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT01318330 Completed HomeoTherapy Co., Ltd 2011-12-31
NCT01309997 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01309997 Completed Fred Hutchinson Cancer Research Center 2014-12-31
NCT01287078 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans https://ClinicalTrials.gov/show/NCT01287078 Completed National Institutes of Health Clinical Center (CC) 2018-08-08
NCT01273207 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans https://ClinicalTrials.gov/show/NCT01273207 Completed National Institutes of Health Clinical Center (CC) 2019-05-10
NCT02040623 Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) https://ClinicalTrials.gov/show/NCT02040623 Completed Rigel Pharmaceuticals 2016-07-31
NCT02032446 Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02032446 Recruiting A.O. Ospedale Papa Giovanni XXIII 2016-09-30
NCT03591874 Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease https://ClinicalTrials.gov/show/NCT03591874 Completed Ocugen 2020-06-15
NCT03339297 An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) https://ClinicalTrials.gov/show/NCT03339297 Completed Jazz Pharmaceuticals 2020-05-12
NCT00529035 Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00529035 Completed Dana-Farber Cancer Institute 2011-06-30
NCT01977781 Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01977781 Completed Massachusetts Eye and Ear Infirmary 2014-09-30
NCT01956903 Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. https://ClinicalTrials.gov/show/NCT01956903 Completed Grupo Espanol de trasplantes hematopoyeticos y terapia celular 2013-09-30
NCT01954979 A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT01954979 Recruiting Dana-Farber Cancer Institute 2020-06-30
NCT01950507 Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01950507 Completed National Institutes of Health Clinical Center (CC) 2018-05-10
NCT01927120 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis https://ClinicalTrials.gov/show/NCT01927120 Completed H. Lee Moffitt Cancer Center and Research Institute 2016-08-25
NCT01926899 A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients https://ClinicalTrials.gov/show/NCT01926899 Completed Indiana University 2018-02-01
NCT01903473 Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) https://ClinicalTrials.gov/show/NCT01903473 Recruiting University of Liege 2021-06-30
NCT01898377 Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children https://ClinicalTrials.gov/show/NCT01898377 Active, not recruiting Seoul National University Hospital 2018-07-31
NCT01883180 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis https://ClinicalTrials.gov/show/NCT01883180 Completed Nanfang Hospital of Southern Medical University 2017-09-30
NCT01862965 Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus https://ClinicalTrials.gov/show/NCT01862965 Completed Universitätsklinikum Hamburg-Eppendorf 2018-02-07
NCT01810718 Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD https://ClinicalTrials.gov/show/NCT01810718 Completed Gruppo Italiano Trapianto di Midollo Osseo 2015-02-28
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) https://ClinicalTrials.gov/show/NCT01804686 Enrolling by invitation Janssen Research & Development, LLC 2026-12-31
NCT01795573 Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01795573 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-31
NCT01790568 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01790568 Completed University of Michigan Rogel Cancer Center 2017-01-01
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01788501 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01788501 Completed Seoul National University Hospital 2017-03-01
NCT01754389 Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01754389 Completed Dana-Farber Cancer Institute 2016-05-31
NCT01743131 Abatacept as GVHD Prophylaxis Phase 2 https://ClinicalTrials.gov/show/NCT01743131 Active, not recruiting Boston Children’s Hospital 2018-06-30
NCT01713400 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01713400 Completed H. Lee Moffitt Cancer Center and Research Institute 2014-10-27
NCT01700036 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease https://ClinicalTrials.gov/show/NCT01700036 Completed University of Michigan Rogel Cancer Center 2016-10-31
NCT01699412 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT01699412 Completed Grupo de Estudos Multicentricos em Onco-Hematologia 2012-07-31
NCT01695668 Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% https://ClinicalTrials.gov/show/NCT01695668 Completed University of Michigan 2013-09-30
NCT01688466 Pomalidomide for Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT01688466 Completed National Institutes of Health Clinical Center (CC) 2017-03-30
NCT01680965 Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01680965 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-09-30
NCT01672229 Bortezomib in Patients With Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01672229 Completed University of California, Davis 2018-04-09
NCT01665677 Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT01665677 Active, not recruiting Medical College of Wisconsin 2023-12-31
NCT01633229 Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications https://ClinicalTrials.gov/show/NCT01633229 Completed National Institutes of Health Clinical Center (CC) 2013-07-01
NCT01616056 Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01616056 Completed Fred Hutchinson Cancer Research Center 2014-10-31
NCT01596218 Brentuximab Vedotin for Steroid Refractory GvHD https://ClinicalTrials.gov/show/NCT01596218 Completed Massachusetts General Hospital 2016-06-30
NCT01557517 Clobetasol for Oral Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01557517 Completed National Institutes of Health Clinical Center (CC) 2017-06-09
NCT01523821 Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) https://ClinicalTrials.gov/show/NCT01523821 Completed Fred Hutchinson Cancer Research Center 2017-01-15
NCT01520623 Complement and Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT01520623 Completed Assistance Publique - Hôpitaux de Paris 2013-02-28
NCT01509560 PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood https://ClinicalTrials.gov/show/NCT01509560 Completed Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH 2016-04-30
NCT01491958 Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01491958 Completed Ohio State University Comprehensive Cancer Center 2014-01-01
NCT01487577 Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention https://ClinicalTrials.gov/show/NCT01487577 Completed University of Pittsburgh 2014-12-31
NCT01463475 University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol https://ClinicalTrials.gov/show/NCT01463475 Completed University of Wisconsin, Madison 2013-12-31
NCT01428973 Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens https://ClinicalTrials.gov/show/NCT01428973 Active, not recruiting University of Liege 2022-09-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01393132 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye https://ClinicalTrials.gov/show/NCT01393132 Completed Michigan Cornea Consultants, PC 2012-12-31
NCT01380535 Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT01380535 Completed Mallinckrodt 2015-03-31
NCT01379209 Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) https://ClinicalTrials.gov/show/NCT01379209 Completed Regimmune Corporation 2015-06-30
NCT01324908 Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis https://ClinicalTrials.gov/show/NCT01324908 Active, not recruiting Vanderbilt-Ingram Cancer Center 2018-01-31
NCT04204122 Vigamox Treatment for Ocular Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT04204122 Recruiting Washington University School of Medicine 2022-07-31
NCT04337515 A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant https://ClinicalTrials.gov/show/NCT04337515 Recruiting University of California, San Francisco 2022-01-01
NCT04291261 Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT04291261 Active, not recruiting Universitätsklinikum Hamburg-Eppendorf 2023-01-31
NCT04290429 Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients https://ClinicalTrials.gov/show/NCT04290429 Completed University of Freiburg 2019-12-06
NCT04285424 FMT for Steroid Resistant Gut Acute GVHD https://ClinicalTrials.gov/show/NCT04285424 Recruiting Affiliated Hospital to Academy of Military Medical Sciences 2021-12-31
NCT04235036 Ibrutinib and Rituxan for Chronic GVHD https://ClinicalTrials.gov/show/NCT04235036 Recruiting Northside Hospital, Inc. 2021-12-31
NCT04227938 Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease https://ClinicalTrials.gov/show/NCT04227938 Recruiting Alpine Immune Sciences, Inc. 2022-05-31
NCT04212416 Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT04212416 Recruiting City of Hope Medical Center 2021-08-02
NCT04200365 A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT04200365 Recruiting SCRI Development Innovations, LLC 2023-06-30
NCT04189432 Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT04189432 Recruiting SCM Lifescience Co., LTD. 2021-03-31
NCT04131738 Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT04131738 Recruiting Washington University School of Medicine 2021-07-31
NCT04111497 Glasdegib for Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT04111497 Recruiting Fred Hutchinson Cancer Research Center 2022-12-31
NCT04014790 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT04014790 Recruiting Regimmune Corporation 2021-08-31
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation https://ClinicalTrials.gov/show/NCT04014413 Recruiting Chinese University of Hong Kong 2023-10-31
NCT03990051 Treatment Safety and Efficacy of Pro-ocularâ„¢ 1% for Chronic Ocular Graft Following Allogeneic HSCT. https://ClinicalTrials.gov/show/NCT03990051 Enrolling by invitation Glia, LLC 2019-10-21
NCT03983850 Optimizing PTCy Dose and Timing https://ClinicalTrials.gov/show/NCT03983850 Recruiting National Institutes of Health Clinical Center (CC) 2024-05-31
NCT03963024 Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT https://ClinicalTrials.gov/show/NCT03963024 Recruiting IRCCS San Raffaele 2019-12-31
NCT03954236 Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03954236 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03945591 High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) https://ClinicalTrials.gov/show/NCT03945591 Recruiting NYU Langone Health 2022-11-30
NCT03924401 Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant https://ClinicalTrials.gov/show/NCT03924401 Recruiting Emory University 2023-12-31
NCT03918343 Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03918343 Recruiting Centre Hospitalier Universitaire de Besancon 2021-11-30
NCT03847844 UCMSCs as Front-line Approach of Treatment for Patients With aGVHD https://ClinicalTrials.gov/show/NCT03847844 Recruiting Cytopeutics Sdn. Bhd. 2021-10-31
NCT03846479 Itacitinib for Low Risk GVHD https://ClinicalTrials.gov/show/NCT03846479 Recruiting Icahn School of Medicine at Mount Sinai 2020-12-31
NCT03842696 Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation https://ClinicalTrials.gov/show/NCT03842696 Recruiting University of Michigan Rogel Cancer Center 2024-02-29
NCT03839069 Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis https://ClinicalTrials.gov/show/NCT03839069 Recruiting National Taiwan University Hospital 2020-12-31
NCT03836690 Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03836690 Recruiting University College, London 2022-07-01
NCT03818334 Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies https://ClinicalTrials.gov/show/NCT03818334 Recruiting Hospital Israelita Albert Einstein 2021-11-01
NCT03805789 The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant https://ClinicalTrials.gov/show/NCT03805789 Recruiting CSL Behring 2022-08-31
NCT03790332 Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT03790332 Recruiting Pharmacyclics LLC. 2021-09-09
NCT03779854 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03779854 Recruiting Fred Hutchinson Cancer Research Center 2022-12-31
NCT03717480 Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03717480 Recruiting Dana-Farber Cancer Institute 2022-05-01
NCT03689894 Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT https://ClinicalTrials.gov/show/NCT03689894 Recruiting Dartmouth-Hitchcock Medical Center 2023-12-31
NCT03689465 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis https://ClinicalTrials.gov/show/NCT03689465 Recruiting Nanfang Hospital of Southern Medical University 2020-09-30
NCT03683498 Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease https://ClinicalTrials.gov/show/NCT03683498 Recruiting Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2019-08-31
NCT03657160 Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation https://ClinicalTrials.gov/show/NCT03657160 Recruiting Takeda 2020-10-23
NCT03616184 Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids https://ClinicalTrials.gov/show/NCT03616184 Recruiting University of Nebraska 2023-04-30
NCT03605927 CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03605927 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2024-01-31
NCT03604692 A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD https://ClinicalTrials.gov/show/NCT03604692 Recruiting Syndax Pharmaceuticals 2020-12-01
NCT03584516 GRAVITAS-309: Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03584516 Recruiting Incyte Corporation 2023-08-17
NCT03546556 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients https://ClinicalTrials.gov/show/NCT03546556 Recruiting UNC Lineberger Comprehensive Cancer Center 2020-12-31
NCT03497273 Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects https://ClinicalTrials.gov/show/NCT03497273 Completed Incyte Corporation 2019-11-30
NCT03491215 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease https://ClinicalTrials.gov/show/NCT03491215 Recruiting Novartis 2022-12-26
NCT03483675 Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT03483675 Active, not recruiting Fred Hutchinson Cancer Research Center 2020-05-14
NCT03474679 A Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) https://ClinicalTrials.gov/show/NCT03474679 Active, not recruiting Janssen Pharmaceutical K.K. 2022-02-28
NCT03459040 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD https://ClinicalTrials.gov/show/NCT03459040 Active, not recruiting Icahn School of Medicine at Mount Sinai 2020-07-31
NCT03434730 Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation https://ClinicalTrials.gov/show/NCT03434730 Recruiting Memorial Sloan Kettering Cancer Center 2021-02-07
NCT03434704 Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole https://ClinicalTrials.gov/show/NCT03434704 Recruiting IRCCS San Raffaele 2020-03-15
NCT03422627 Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT03422627 Recruiting Amgen 2023-05-22
NCT03415867 Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT03415867 Active, not recruiting Grupo Espanol de trasplantes hematopoyeticos y terapia celular 2023-01-09
NCT03414645 Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease https://ClinicalTrials.gov/show/NCT03414645 Recruiting Cambium Medical Technologies LLC 2019-09-30
NCT01240525 Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers https://ClinicalTrials.gov/show/NCT01240525 Active, not recruiting University College, London 2019-11-30
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01222039 Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease. https://ClinicalTrials.gov/show/NCT01222039 Completed Andalusian Network for Design and Translation of Advanced Therapies 2014-06-30
NCT01188798 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01188798 Completed St. Jude Children’s Research Hospital 2012-02-29
NCT01175148 Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation https://ClinicalTrials.gov/show/NCT01175148 Completed West Virginia University 2014-12-31
NCT01174940 Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01174940 Completed University of Kansas Medical Center 2014-08-31
NCT01161628 Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT01161628 Completed Northside Hospital, Inc. 2014-01-31
NCT01155817 Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01155817 Completed Stanford University 2013-12-31
NCT01135641 Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD) https://ClinicalTrials.gov/show/NCT01135641 Completed Nantes University Hospital 2014-03-31
NCT01111526 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT01111526 Completed H. Lee Moffitt Cancer Center and Research Institute 2015-10-31
NCT01106833 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) https://ClinicalTrials.gov/show/NCT01106833 Completed Medical College of Wisconsin 2017-02-14
NCT01042509 Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01042509 Completed Hospital Universitario Dr. Jose E. Gonzalez 2011-10-31
NCT01002742 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) https://ClinicalTrials.gov/show/NCT01002742 Completed Medical College of Wisconsin 2012-01-31
NCT00993343 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00993343 Completed Karolinska Institutet 2015-02-28
NCT00967096 Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) https://ClinicalTrials.gov/show/NCT00967096 Completed Emory University 2009-04-30
NCT00948753 Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation https://ClinicalTrials.gov/show/NCT00948753 Completed Abramson Cancer Center of the University of Pennsylvania 2011-04-30
NCT00948727 Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation https://ClinicalTrials.gov/show/NCT00948727 Completed Assistance Publique - Hôpitaux de Paris 2006-09-30
NCT00929695 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT00929695 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00923845 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer https://ClinicalTrials.gov/show/NCT00923845 Completed National Institutes of Health Clinical Center (CC) 2015-06-01
NCT00914940 Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD https://ClinicalTrials.gov/show/NCT00914940 Completed Fred Hutchinson Cancer Research Center 2019-12-01
NCT00887263 Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) https://ClinicalTrials.gov/show/NCT00887263 Completed Dr. Falk Pharma GmbH 2015-10-31
NCT03297528 Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant https://ClinicalTrials.gov/show/NCT03297528 Recruiting Peking University People’s Hospital 2020-10-01
NCT00827398 Treatment of Steroid Resistant GVHD by Infusion MSC https://ClinicalTrials.gov/show/NCT00827398 Completed UMC Utrecht 2013-07-31
NCT00824889 Exploratory Study of Natural Killer Cells in Human Skin https://ClinicalTrials.gov/show/NCT00824889 Completed Assistance Publique Hopitaux De Marseille 2011-11-30
NCT03819803 Fecal Microbiota Transplantation in aGvHD After ASCT https://ClinicalTrials.gov/show/NCT03819803 Recruiting Medical University of Graz 2020-03-01
NCT03192397 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03192397 Recruiting Roswell Park Cancer Institute 2021-07-01
NCT00815919 Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00815919 Completed Dana-Farber Cancer Institute 2012-01-31
NCT00813618 Study of MEDI 507 in the Treatment of Pediatric Patients https://ClinicalTrials.gov/show/NCT00813618 Completed MedImmune LLC 2004-06-30
NCT00810602 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00810602 Completed University of Michigan Rogel Cancer Center 2013-04-30
NCT01453140 In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT01453140 Completed Hackensack Meridian Health 2012-03-31
NCT00806728 Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00806728 Completed MedImmune LLC 1998-11-30
NCT00806208 Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD) https://ClinicalTrials.gov/show/NCT00806208 Completed MedImmune LLC 2000-01-31
NCT03764228 Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03764228 Recruiting Peking University People’s Hospital 2021-07-01
NCT03763318 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD https://ClinicalTrials.gov/show/NCT03763318 Recruiting Equillium 2021-05-31
NCT00803010 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT00803010 Completed H. Lee Moffitt Cancer Center and Research Institute 2012-12-31
NCT02525029 Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD https://ClinicalTrials.gov/show/NCT02525029 Active, not recruiting Masonic Cancer Center, University of Minnesota 2021-01-31
NCT03082677 Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03082677 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT02841995 A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02841995 Active, not recruiting Kadmon Corporation, LLC 2020-10-31
NCT00792246 Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00792246 Completed Duke University 2012-07-31
NCT00775632 Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants https://ClinicalTrials.gov/show/NCT00775632 Completed University Health Network, Toronto 2010-09-30
NCT00770757 CC-4047 (Pomalidomide) for Graft vs. Host Disease https://ClinicalTrials.gov/show/NCT00770757 Completed Washington University School of Medicine 2010-10-31
NCT00760981 A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00760981 Completed Stanford University 2012-04-30
NCT00755040 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder https://ClinicalTrials.gov/show/NCT00755040 Completed Vanderbilt-Ingram Cancer Center 2014-12-31
NCT00726375 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00726375 Completed University of Michigan Rogel Cancer Center 2013-07-31
NCT00702689 Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00702689 Completed National Institutes of Health Clinical Center (CC) 2011-05-18
NCT00691015 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00691015 Completed Barbara Ann Karmanos Cancer Institute 2014-04-30
NCT00686855 Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00686855 Completed Dana-Farber Cancer Institute 2012-12-31
NCT00678275 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia https://ClinicalTrials.gov/show/NCT00678275 Completed Universitätsklinikum Hamburg-Eppendorf 2014-02-28
NCT00670423 A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation https://ClinicalTrials.gov/show/NCT00670423 Completed Indiana University 2012-07-05
NCT00656058 Montelukast to Treat Bronchiolitis Obliterans https://ClinicalTrials.gov/show/NCT00656058 Completed National Institutes of Health Clinical Center (CC) 2014-05-02
NCT00655343 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) https://ClinicalTrials.gov/show/NCT00655343 Completed Neovii Biotech 2007-03-31
NCT00639717 Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00639717 Completed University of Michigan Rogel Cancer Center 2012-01-31
NCT00611351 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00611351 Completed University of Nebraska 2008-02-29
NCT00609609 Photopheresis for the Treatment of Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00609609 Completed M.D. Anderson Cancer Center 2016-01-31
NCT00603330 Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function https://ClinicalTrials.gov/show/NCT00603330 Recruiting University of Liege 2020-09-01
NCT00589563 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer https://ClinicalTrials.gov/show/NCT00589563 Completed City of Hope Medical Center 2012-02-29
NCT00577278 Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00577278 Active, not recruiting City of Hope Medical Center 2019-12-31
NCT00574470 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD https://ClinicalTrials.gov/show/NCT00574470 Completed University of Iowa 2007-11-30
NCT00562497 Efficacy and Safety of Prochymalâ„¢ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT00562497 Completed Mesoblast, Ltd. 2009-07-14
NCT00544115 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders https://ClinicalTrials.gov/show/NCT00544115 Active, not recruiting City of Hope Medical Center 2019-11-30
NCT00513474 Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00513474 Completed Massachusetts General Hospital 2013-02-12
NCT00504803 Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT00504803 Completed University of Liege 2010-12-31
NCT00495755 Campath in Chronic GVHD https://ClinicalTrials.gov/show/NCT00495755 Completed Dana-Farber Cancer Institute 2011-10-31
NCT00492921 High-Dose Cyclophosphamide for Steroid Refractory GVHD https://ClinicalTrials.gov/show/NCT00492921 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2013-01-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00438958 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases https://ClinicalTrials.gov/show/NCT00438958 Completed National Cancer Institute (NCI) NA
NCT00423514 Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease https://ClinicalTrials.gov/show/NCT00423514 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT00410657 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00410657 Completed Fred Hutchinson Cancer Research Center 2006-11-30
NCT00408928 Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00408928 Completed Thomas Jefferson University 2008-09-30
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00406393 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) https://ClinicalTrials.gov/show/NCT00406393 Completed Medical College of Wisconsin 2012-10-31
NCT00397332 Alefacept for Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00397332 Completed Hadassah Medical Organization 2013-01-31
NCT00391170 Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT00391170 Recruiting National Institutes of Health Clinical Center (CC) 2023-06-30
NCT00388362 Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00388362 Completed Stanford University 2010-11-30
NCT00382109 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission https://ClinicalTrials.gov/show/NCT00382109 Completed Children’s Oncology Group 2011-05-31
NCT00369226 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00369226 Completed Dana-Farber Cancer Institute 2010-07-31
NCT00366145 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00366145 Completed Mesoblast, Ltd. 2008-12-26
NCT00361049 Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00361049 Completed Case Comprehensive Cancer Center 2009-06-30
NCT00360685 Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX https://ClinicalTrials.gov/show/NCT00360685 Completed H. Lee Moffitt Cancer Center and Research Institute 2011-01-31
NCT00357084 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00357084 Completed Fred Hutchinson Cancer Research Center 2007-08-31
NCT00350545 A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00350545 Completed Stanford University 2012-05-31
NCT00350181 Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant https://ClinicalTrials.gov/show/NCT00350181 Completed Stanford University 2007-08-31
NCT00346359 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer https://ClinicalTrials.gov/show/NCT00346359 Completed Fred Hutchinson Cancer Research Center NA
NCT00284986 Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients https://ClinicalTrials.gov/show/NCT00284986 Completed Mesoblast, Ltd. 2006-04-25
NCT00282282 Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00282282 Completed Dana-Farber Cancer Institute 2009-01-31
NCT00265837 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00265837 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2007-08-31
NCT02953678 A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) https://ClinicalTrials.gov/show/NCT02953678 Active, not recruiting Incyte Corporation 2018-01-31
NCT00255710 Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00255710 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
NCT00248430 Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer https://ClinicalTrials.gov/show/NCT00248430 Completed Fred Hutchinson Cancer Research Center NA
NCT00248365 Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD) https://ClinicalTrials.gov/show/NCT00248365 Completed Kiadis Pharma NA
NCT00233896 Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD https://ClinicalTrials.gov/show/NCT00233896 Completed Enteron Pharmaceuticals NA
NCT00228839 GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00228839 Completed Emory University NA
NCT00224874 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) https://ClinicalTrials.gov/show/NCT00224874 Completed National Heart, Lung, and Blood Institute (NHLBI) 2009-01-31
NCT00201799 Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00201799 Completed Ohio State University Comprehensive Cancer Center 2006-08-31
NCT00201786 Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00201786 Completed Ohio State University Comprehensive Cancer Center 2007-10-31
NCT00195481 Study Evaluating Sirolimus in Kidney Transplant Recipients in India https://ClinicalTrials.gov/show/NCT00195481 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-12-31
NCT00195468 Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus https://ClinicalTrials.gov/show/NCT00195468 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-11-30
NCT00195429 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT00195429 Completed Wyeth is now a wholly owned subsidiary of Pfizer NA
NCT00195273 Study Evaluating Sirolimus in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT00195273 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-07-31
NCT00189748 A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension- https://ClinicalTrials.gov/show/NCT00189748 Completed Astellas Pharma Inc NA
NCT00189488 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation https://ClinicalTrials.gov/show/NCT00189488 Completed Swedish Orphan Biovitrum 2008-11-30
NCT00186667 Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00186667 Completed Stanford University 2000-01-31
NCT00185692 Allogeneic Transplantation From Related Haploidentical Donors https://ClinicalTrials.gov/show/NCT00185692 Completed Stanford University 2010-12-31
NCT00180089 Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00180089 Completed Technische Universität Dresden 2009-03-31
NCT00167947 Study Evaluating Sirolimus in Kidney Transplant Recipients. https://ClinicalTrials.gov/show/NCT00167947 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2007-07-31
NCT00146978 Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT00146978 Completed Hadassah Medical Organization NA
NCT00146614 Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00146614 Completed Dana-Farber Cancer Institute 2003-04-30
NCT00144703 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00144703 Completed Dana-Farber Cancer Institute 2006-11-30
NCT00144677 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00144677 Completed Dana-Farber Cancer Institute 2006-06-30
NCT00144430 Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children https://ClinicalTrials.gov/show/NCT00144430 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2008-08-31
NCT00141739 Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) https://ClinicalTrials.gov/show/NCT00141739 Completed University of Michigan Rogel Cancer Center 2011-08-31
NCT00141713 The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00141713 Completed University of Michigan Rogel Cancer Center 2006-11-30
NCT00136903 Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD) https://ClinicalTrials.gov/show/NCT00136903 Completed Mesoblast, Ltd. 2006-07-28
NCT00136396 Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00136396 Completed Dana-Farber Cancer Institute 2006-11-30
NCT00130754 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation https://ClinicalTrials.gov/show/NCT00130754 Completed Hadassah Medical Organization NA
NCT00128739 Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00128739 Completed Rafa Laboratories NA
NCT00102583 Cyclosporine Implant for Ocular Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00102583 Completed National Institutes of Health Clinical Center (CC) 2011-03-15
NCT00096161 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00096161 Completed Fred Hutchinson Cancer Research Center 2015-02-28
NCT00096096 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00096096 Completed Fred Hutchinson Cancer Research Center 2006-05-31
NCT00089037 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00089037 Completed Fred Hutchinson Cancer Research Center 2005-04-30
NCT00003662 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases https://ClinicalTrials.gov/show/NCT00003662 Completed Roswell Park Cancer Institute 2001-01-31
NCT00003661 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003661 Completed Roswell Park Cancer Institute 1999-11-30
NCT00088543 Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00088543 Completed Sanofi 2006-04-30
NCT00002833 Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00002833 Completed M.D. Anderson Cancer Center 2002-04-30
NCT00003894 Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant https://ClinicalTrials.gov/show/NCT00003894 Completed Roswell Park Cancer Institute 2000-01-31
NCT00005988 Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy https://ClinicalTrials.gov/show/NCT00005988 Completed Dana-Farber Cancer Institute 2001-06-16
NCT00003398 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003398 Completed University of Maryland, Baltimore 2000-05-31
NCT00003270 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003270 Completed Roswell Park Cancer Institute 2017-10-16
NCT00002456 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00002456 Completed Fred Hutchinson Cancer Research Center NA
NCT00010283 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon https://ClinicalTrials.gov/show/NCT00010283 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00079183 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment https://ClinicalTrials.gov/show/NCT00079183 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00004904 Stem Cell Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00004904 Completed Northwestern University 2000-07-31
NCT00074035 Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00074035 Completed Alliance for Clinical Trials in Oncology 2008-08-31
NCT00003414 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003414 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2004-05-31
NCT00004255 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00004255 Completed National Cancer Institute (NCI) NA
NCT00004232 Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00004232 Completed Northwestern University 2002-10-31
NCT00056875 Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants https://ClinicalTrials.gov/show/NCT00056875 Completed FDA Office of Orphan Products Development NA
NCT00055666 Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract https://ClinicalTrials.gov/show/NCT00055666 Completed Roswell Park Cancer Institute 2005-02-28
NCT00054613 Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT00054613 Completed Mallinckrodt NA
NCT00054600 Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT00054600 Completed Mallinckrodt NA
NCT00054340 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder https://ClinicalTrials.gov/show/NCT00054340 Completed Fred Hutchinson Cancer Research Center NA
NCT00053976 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00053976 Completed Dana-Farber Cancer Institute 2003-11-30
NCT00053157 Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia https://ClinicalTrials.gov/show/NCT00053157 Completed Roswell Park Cancer Institute 2004-08-31
NCT00043147 Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00043147 Completed National Cancer Institute (NCI) NA
NCT00031824 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00031824 Completed Children’s Oncology Group 2005-05-31
NCT00025662 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS https://ClinicalTrials.gov/show/NCT00025662 Completed National Institutes of Health Clinical Center (CC) 2008-02-29
NCT00014469 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer https://ClinicalTrials.gov/show/NCT00014469 Completed Memorial Sloan Kettering Cancer Center 2007-05-31
NCT00003538 Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00003538 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2004-05-31
NCT00003335 Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003335 Completed Case Comprehensive Cancer Center 2007-11-30
NCT00001748 HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies https://ClinicalTrials.gov/show/NCT00001748 Completed National Institutes of Health Clinical Center (CC) NA
NCT00048789 Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00048789 Completed National Institutes of Health Clinical Center (CC) NA
NCT00044720 Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT00044720 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-07-31
NCT00037531 Study Evaluating Sirolimus (Rapamuneâ„¢) in Solid Organ Transplant Recipients https://ClinicalTrials.gov/show/NCT00037531 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2004-08-31
NCT00035880 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00035880 Completed Abgenix NA
NCT00032292 Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT00032292 Completed Facet Biotech 2006-08-31
NCT00031148 Keratinocyte Growth Factor to Prevent Acute GVHD https://ClinicalTrials.gov/show/NCT00031148 Completed FDA Office of Orphan Products Development NA
NCT00006747 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00006747 Completed Alliance for Clinical Trials in Oncology 2003-02-28
NCT00023530 Blood and Marrow Transplant Clinical Research Network https://ClinicalTrials.gov/show/NCT00023530 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00189761 A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients https://ClinicalTrials.gov/show/NCT00189761 Completed Astellas Pharma Inc NA
NCT00109993 Campath-1H + FK506 and Methylprednisolone for GVHD https://ClinicalTrials.gov/show/NCT00109993 Completed Case Comprehensive Cancer Center 2006-06-30
NCT00007059 Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation https://ClinicalTrials.gov/show/NCT00007059 Completed National Center for Research Resources (NCRR) NA
NCT00001873 The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers https://ClinicalTrials.gov/show/NCT00001873 Completed National Institutes of Health Clinical Center (CC) 2007-12-28
NCT00001830 Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants https://ClinicalTrials.gov/show/NCT00001830 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001637 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults https://ClinicalTrials.gov/show/NCT00001637 Completed National Institutes of Health Clinical Center (CC) 2008-07-28
NCT00001623 Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia https://ClinicalTrials.gov/show/NCT00001623 Completed National Institutes of Health Clinical Center (CC) 2008-01-31
NCT00001561 Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation https://ClinicalTrials.gov/show/NCT00001561 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001144 Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00001144 Completed National Institutes of Health Clinical Center (CC) NA
NCT00000591 T-Cell Depletion in Unrelated Donor Marrow Transplantation https://ClinicalTrials.gov/show/NCT00000591 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04038827 Origin of CEC in Patients After Allo-HSCT https://ClinicalTrials.gov/show/NCT04038827 Completed Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 2020-01-31
NCT03369353 Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) https://ClinicalTrials.gov/show/NCT03369353 Enrolling by invitation Boston Children’s Hospital 2021-01-31
NCT03148743 Fecal Microbiota Transplantation in Gut aGVHD Treated https://ClinicalTrials.gov/show/NCT03148743 Recruiting The First Affiliated Hospital of Soochow University 2020-12-31
NCT02991846 A Prospective Observational Study for Evaluating CGVHD https://ClinicalTrials.gov/show/NCT02991846 Recruiting Gruppo Italiano Trapianto di Midollo Osseo 2022-09-30
NCT04431479 Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study https://ClinicalTrials.gov/show/NCT04431479 Recruiting Fred Hutchinson Cancer Research Center 2024-08-02
NCT02712762 Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients https://ClinicalTrials.gov/show/NCT02712762 Recruiting Singapore National Eye Centre 2020-11-30
NCT02611180 Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT02611180 Recruiting Washington University School of Medicine 2021-04-30
NCT00106925 Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants https://ClinicalTrials.gov/show/NCT00106925 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00092235 Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00092235 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02411474 Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD https://ClinicalTrials.gov/show/NCT02411474 Completed Yonsei University 2014-08-31
NCT02409134 Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat https://ClinicalTrials.gov/show/NCT02409134 Completed University of Michigan Rogel Cancer Center 2018-04-30
NCT02398708 Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT https://ClinicalTrials.gov/show/NCT02398708 Completed University of Florida 2016-04-30
NCT02319226 Toward Immune Biomarkers for Tolerance and GvHD in Humans https://ClinicalTrials.gov/show/NCT02319226 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2019-02-28
NCT02194439 Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT02194439 Active, not recruiting Indiana University 2021-05-31
NCT02175615 Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT https://ClinicalTrials.gov/show/NCT02175615 Completed The Hospital for Sick Children 2015-12-31
NCT02067832 Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT02067832 Active, not recruiting University of British Columbia 2022-03-31
NCT02064972 CEC Count Changes to Support GvHD Diagnosis. https://ClinicalTrials.gov/show/NCT02064972 Completed Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 2016-03-31
NCT01902576 Chronic GVHD Response Measures Validation https://ClinicalTrials.gov/show/NCT01902576 Active, not recruiting Fred Hutchinson Cancer Research Center 2019-09-26
NCT01851382 Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research https://ClinicalTrials.gov/show/NCT01851382 Completed National Institutes of Health Clinical Center (CC) 2014-07-10
NCT01521039 Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT01521039 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT01512498 Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche https://ClinicalTrials.gov/show/NCT01512498 Completed Hadassah Medical Organization 2018-12-31
NCT01460914 Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment https://ClinicalTrials.gov/show/NCT01460914 Active, not recruiting Dartmouth-Hitchcock Medical Center 2050-09-30
NCT04342442 Identification of Novel Targetable Kinases in SR-a GvHD https://ClinicalTrials.gov/show/NCT04342442 Completed University of Freiburg 2019-12-31
NCT04044365 Pediatric cGVHD Symptom Scale https://ClinicalTrials.gov/show/NCT04044365 Recruiting National Institutes of Health Clinical Center (CC) 2022-06-01
NCT03727113 Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors https://ClinicalTrials.gov/show/NCT03727113 Recruiting Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2020-03-31
NCT03602599 Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls https://ClinicalTrials.gov/show/NCT03602599 Recruiting National Institutes of Health Clinical Center (CC) 2023-05-31
NCT03557749 Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies https://ClinicalTrials.gov/show/NCT03557749 Recruiting Masonic Cancer Center, University of Minnesota 2030-01-31
NCT03438643 Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT03438643 Recruiting University Hospital, Lille 2021-03-31
NCT03419078 Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) https://ClinicalTrials.gov/show/NCT03419078 Completed Imperial College Healthcare NHS Trust 2016-06-30
NCT01234623 Cord Blood Serum in the Treatment of Ocular Surface Diseases https://ClinicalTrials.gov/show/NCT01234623 Completed Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 2011-05-31
NCT01221766 Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT01221766 Completed Dana-Farber Cancer Institute 2013-04-30
NCT01206309 Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT01206309 Completed Fred Hutchinson Cancer Research Center 2016-10-31
NCT01174277 Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy. https://ClinicalTrials.gov/show/NCT01174277 Completed University of Kansas Medical Center 2016-02-29
NCT01036958 Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT01036958 Completed National Institutes of Health Clinical Center (CC) NA
NCT00900406 Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00900406 Completed Vanderbilt-Ingram Cancer Center 2010-03-31
NCT00898885 Analysis of the Clinical and Histological Correlation of Oral Graft-Versus-Host-Disease (GVHD) https://ClinicalTrials.gov/show/NCT00898885 Completed University of Sao Paulo 2008-10-31
NCT01369914 The Natural History of Graft-Versus-Host Disease in the Eyes https://ClinicalTrials.gov/show/NCT01369914 Completed National Institutes of Health Clinical Center (CC) NA
NCT01758250 Microvascular and Fibrosis Imaging Study https://ClinicalTrials.gov/show/NCT01758250 Recruiting Duke University 2020-12-31
NCT00128973 Evaluation of Patients With Immune Function Abnormalities https://ClinicalTrials.gov/show/NCT00128973 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00637689 Improving Outcomes Assessment in Chronic GVHD https://ClinicalTrials.gov/show/NCT00637689 Active, not recruiting Fred Hutchinson Cancer Research Center 2017-05-31
NCT00632658 Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease https://ClinicalTrials.gov/show/NCT00632658 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2011-07-31
NCT00579397 Markers of Inflammation in Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00579397 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2008-10-31
NCT00506233 Feasibility Study of Collecting Multicenter Chronic GVHD Data https://ClinicalTrials.gov/show/NCT00506233 Completed M.D. Anderson Cancer Center 2007-09-30
NCT00353106 Experience of Having Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT00353106 Completed M.D. Anderson Cancer Center 2010-01-31
NCT00179075 Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00179075 Completed Vanderbilt University NA
NCT00179049 Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00179049 Completed Vanderbilt University NA
NCT00023491 Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells https://ClinicalTrials.gov/show/NCT00023491 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001872 Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease https://ClinicalTrials.gov/show/NCT00001872 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001529 Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives https://ClinicalTrials.gov/show/NCT00001529 Recruiting National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03124056 Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT03124056 Completed Fundación para la Investigación del Hospital Clínico de Valencia 2017-02-28
NCT03731624 Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders https://ClinicalTrials.gov/show/NCT03731624 Recruiting Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 2020-12-31
NCT03575767 Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT https://ClinicalTrials.gov/show/NCT03575767 Completed Affiliated Hospital to Academy of Military Medical Sciences 2018-08-20